$Carisma Therapeutics(CARM.US)$ NEWS Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte Carisma Therapeutics (Nasdaq: CARM) has dosed the first patient in its Phase 1 clinical trial of CT-0525, a novel CAR-Monocyte cellular therapy targeting HER2-overexpressing solid tumors. This marks the first human trial for CAR-Monocytes in a solid tumor setting. Initial data is anticipated by year-end 2024. The trial, open-label in ...
$Carisma Therapeutics(CARM.US)$ NEWS Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
Carisma Therapeutics' low P/S ratio may be due to limited future growth expectations. Its underwhelming revenue outlook contributes to this low P/S, making a significant share price rise unlikely soon.
$Carisma Therapeutics(CARM.US)$Carisma Therapeutics Has Nominated Its First Lead Candidate Under The Collaboration With Moderna That Will Target An Antigen Present On A Solid Tumor
Concerns are rising for Carisma Therapeutics following a downgrade as growth expectations fall behind wider market. This could trigger further cuts if the industry deteriorates. Analysts currently bear a grim outlook.
Carisma Therapeutics股票討論區
NEWS
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics (Nasdaq: CARM) has dosed the first patient in its Phase 1 clinical trial of CT-0525, a novel CAR-Monocyte cellular therapy targeting HER2-overexpressing solid tumors. This marks the first human trial for CAR-Monocytes in a solid tumor setting. Initial data is anticipated by year-end 2024. The trial, open-label in ...
NEWS
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
$Carisma Therapeutics(CARM.US)$ buy 🏆🔥💴
FDA news but dipping ?
暫無評論